BFLY vs. TRVI, INMB, IPSC, CDT, INGN, OPT, KOD, PIII, ZVRA, and PROF
Should you be buying Butterfly Network stock or one of its competitors? The main competitors of Butterfly Network include Trevi Therapeutics (TRVI), INmune Bio (INMB), Century Therapeutics (IPSC), Conduit Pharmaceuticals (CDT), Inogen (INGN), Opthea (OPT), Kodiak Sciences (KOD), P3 Health Partners (PIII), Zevra Therapeutics (ZVRA), and Profound Medical (PROF). These companies are all part of the "medical" sector.
Butterfly Network (NYSE:BFLY) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, community ranking, media sentiment and institutional ownership.
Trevi Therapeutics received 73 more outperform votes than Butterfly Network when rated by MarketBeat users. However, 62.50% of users gave Butterfly Network an outperform vote while only 60.94% of users gave Trevi Therapeutics an outperform vote.
In the previous week, Trevi Therapeutics had 3 more articles in the media than Butterfly Network. MarketBeat recorded 5 mentions for Trevi Therapeutics and 2 mentions for Butterfly Network. Trevi Therapeutics' average media sentiment score of 0.49 beat Butterfly Network's score of 0.47 indicating that Trevi Therapeutics is being referred to more favorably in the news media.
Butterfly Network has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500.
37.9% of Butterfly Network shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 27.2% of Butterfly Network shares are owned by company insiders. Comparatively, 27.5% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Trevi Therapeutics has lower revenue, but higher earnings than Butterfly Network. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Butterfly Network, indicating that it is currently the more affordable of the two stocks.
Trevi Therapeutics has a consensus price target of $8.50, indicating a potential upside of 206.86%. Given Trevi Therapeutics' higher possible upside, analysts clearly believe Trevi Therapeutics is more favorable than Butterfly Network.
Trevi Therapeutics has a net margin of 0.00% compared to Butterfly Network's net margin of -179.09%. Trevi Therapeutics' return on equity of -39.54% beat Butterfly Network's return on equity.
Summary
Trevi Therapeutics beats Butterfly Network on 11 of the 16 factors compared between the two stocks.
Get Butterfly Network News Delivered to You Automatically
Sign up to receive the latest news and ratings for BFLY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BFLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Butterfly Network Competitors List
Related Companies and Tools
